Bacteriophages used in COVID patients with resistant bacterial infections
Eight COVID-19 patients in Texas who have secondary carbapenem-resistant Acinetobacter baumannii (CRAB) infections are receiving investigational bacteriophage therapy from biotechnology company Adaptive Phage Therapeutics (APT), company officials announced yesterday.
In collaboration with the Walter Reed Army Institute of Research, Bacterial Diseases Branch, APT scientists identified two bacteriophages from the company's PhageBank library that were active against bacterial isolates from the hospitalized patients, and they are using those phages to treat the patients under Food and Drug Administration (FDA) emergency Investigational New Drug requests. The company also says it's receiving and analyzing CRAB isolates from new patients daily to identify other potential bacteriophage matches.
The use of bacteriophage therapy in the eight patients came in response to requests in late September from the Rio Grande Valley Collaborative (RGVC), a network of 11 healthcare facilities in south Texas treating COVID-19 patients. RGVC data revealed that mortality rates were more than twice as high in COVID-19 patients with secondary CRAB infections than those without secondary CRAB infections.
"We are pleased to have been able to successfully deploy our investigational PhageBank therapy in response to this outbreak in COVID-19 patients in Texas," Greg Merril, APT's CEO and co-founder, said in a press release. "Our PhageBank deployment represents the first time our technology, originally developed by the Department of Defense, has been used to treat multidrug-resistant secondary bacterial infections in COVID-19 patients."
Merril said the company is working with the FDA to expand early access to PhageBank–based therapies for COVID-19 patients.
Nov 2 APT press release
ED study finds high rate of antibiotics for asymptomatic bacteriuria
A study of hospitalized patients admitted through the emergency department (ED) for asymptomatic bacteriuria (ASB) at more than 40 hospitals found that nearly 75% received antibiotics, US researchers reported today in Open Forum Infectious Diseases.
The study, which included 43 hospitals participating in the Michigan Hospital Medicine Safety Consortium, looked at all patients with ASB who were admitted through the ED February 2018 through February 2020. ASB is frequent among hospitalized patients and is commonly treated with antibiotics, even though national guidelines recommend against antibiotic therapy. Because unnecessary antibiotic treatment is common in EDs, the researchers wanted to evaluate how often antibiotic treatment for ASBs is initiated by emergency medicine (EM) clinicians.
The primary outcomes was the percentage of patients who had antibiotic treatment initiated by an EM clinician, and secondary outcomes included length of hospitalization and Clostridioides difficile infection within 30 days. The researchers also assessed factors associated with antibiotic treatment and length of antibiotic therapy.
Of the 2,461 patients admitted through the ED and ultimately determined to have ASB, 1,830 (74.4%) were treated with antibiotics, with a median treatment duration of 6 days. Urine cultures were ordered by EM clinicians in 1,970 patients (80%), and antibiotic treatment was initiated by an EM clinician in 68.5% of those treated with antibiotics (1,253 of 1,830). When antibiotic treatment was initiated by EM clinicians, 79.2% (993 of 1,253) of patients remained on an antibiotic for 3 or more days.
Predictors of EM clinician treatment of ASB versus no treatment included dementia (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.11 to 1.84), spinal cord injury (OR, 5.92; 95% CI, 1.36 to 25.72), presence of a urinary catheter (OR, 1.54; 95% CI, 1.17 to 2.03), incontinence (OR, 1.81; 95% CI, 1.40 to 2.33), and altered mental status (OR, 2.34; 95% CI, 1.82 to 3.00). Patients treated with antibiotics were more likely to have C difficile infection than those who didn't receive antibiotics (0.9% vs 0%) and have longer hospital stays (5.1 vs 4.2 days).
"These findings identify the ED as a key target to reduce antibiotic use and improve outcomes in hospitalized patients with ASB," the authors wrote.
Nov 3 Open Forum Infect Dis abstract
UK reports high-path H5N8 avian flu at poultry farm
The United Kingdom yesterday announced that H5N8 avian flu has been detected at a broiler breeding farm in Cheshire, which comes just after veterinary officials detailed an unrelated low-pathogenic H5N2 outbreak at a farm in Kent.
Today the Department for Environment, Food, and Rural Affairs (DEFRA) confirmed that the outbreak was caused by a highly pathogenic strain.
The farm's 13,000 birds will be culled to curb the spread of the virus, and control zones have been placed around the affected location. An investigation is under way into the source of the virus, and DEFRA noted that wild birds migrating from the European mainland can spread avian flu to poultry and other captive birds.
Over the past few months, Russia and its neighbor Kazakhstan have reported a small but steady stream of highly pathogenic H5N8 avian flu outbreaks, which prompted earlier warnings from UK animal health officials for farmers to be vigilant and take precautions. The Netherlands recently reported highly pathogenic H5N8 in wild swans and a highly pathogenic H5 outbreak in poultry.
Nov 2 DEFRA update
Nov 3 DEFRA update